[1]夏 铭,张正坤,曾海龙,等.四种疗法治疗幽门螺杆菌阳性消化性溃疡疗效分析[J].医学信息,2018,31(11):18-21.[doi:10.3969/j.issn.1006-1959.2018.11.006]
　XIA Ming,ZHANG Zheng-kun,ZENG Hai-long,et al.Therapeutic Effect of Four Kinds of Therapy on Helicobacter Pylori Positive Peptic Ulcer[J].Journal of Medical Information,2018,31(11):18-21.[doi:10.3969/j.issn.1006-1959.2018.11.006]
点击复制

四种疗法治疗幽门螺杆菌阳性消化性溃疡疗效分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年11期
页码:
18-21
栏目:
出版日期:
2018-06-01

文章信息/Info

Title:
Therapeutic Effect of Four Kinds of Therapy on Helicobacter Pylori Positive Peptic Ulcer
文章编号:
1006-1959（2018）11-0018-04
作者:
夏 铭; 张正坤; 曾海龙; 王 伟
甘肃省酒泉市人民医院消化科，甘肃 酒泉 735000
Author(s):
XIA Ming; ZHANG Zheng-kun; ZENG Hai-long; WANG Wei
Department of Gastroenterology,Jiuquan Municipal People's Hospital,Jiuquan 735000,Gansu,China
关键词:
雷贝拉唑; 奥美拉唑; 幽门螺旋杆菌; 消化性溃疡
Keywords:
Key words：Rabeprazole; Omeprazole; Helicobacter pylori; Peptic ulcer
分类号:
R632.1
DOI:
10.3969/j.issn.1006-1959.2018.11.006
文献标志码:
A
摘要:
目的 使用四种不同疗法治疗幽门螺杆菌阳性消化性溃疡并比较其疗效。方法 选取2014年9月~2017年5月到我院就诊的245例幽门螺杆菌阳性消化性溃疡的患者，依给药方式的不同分为四组，分别为组1雷贝拉唑四联疗法治疗组60例，组2雷贝拉唑三联疗法治疗组60例，组3奥美拉唑四联疗法治疗组62例，组4奥美拉唑三联疗法治疗组63例，比较4种不同给药方式对幽门螺杆菌阳性消化性溃疡的疗效。结果 组1、组2治疗总有效率均为98.33%，组3总有效率为95.16%，组4总有效率为93.65%。从整体治疗效果上看，雷贝拉唑优于奥美拉唑，差异具有统计学意义（P＜0.05）。在雷贝拉唑治疗组中，雷贝拉唑四联疗法有效率为91.30%，雷贝拉唑三联疗法有效率为73.80%，二者具有统计学意义（P＜0.05）；在奥美拉唑治疗组中，奥美拉唑四联疗法有效率为73.91%，奥美拉唑三联疗法有效率为58.12%，二者间有统计学意义（P＜0.05）；比较雷贝拉唑四联疗法和奥美拉唑四联疗法的有效率，差异具有统计学意义（P＜0.05），雷贝拉唑四联疗法优于奥美拉唑四联疗法；比较雷贝拉唑三联疗法和奥美拉唑三联疗法的有效率，差异具有统计学意义（P＜0.05），雷贝拉唑三联疗法疗效优于奥美拉唑三联疗法。在幽门螺旋杆菌的清除上，雷贝拉唑优于奥美拉唑，四联疗法优于三联疗法。结论 在治疗幽门螺杆菌阳性消化性溃疡中，雷贝拉唑四联疗法表现出最佳的治疗效果。
Abstract:
Abstract：Objective To use four different therapies to treat Helicobacter pylori-positive peptic ulcer and compare its efficacy. Methods A total of 245 patients with Helicobacter pylori-positive peptic ulcer who were admitted to our hospital from September 2014 to May 2017 were divided into four groups according to the different methods of administration.There were 60 cases of group 1 rabeprazole quadruple therapy group,group 2 of rabeprazole triple therapy group 60 cases,group 3 of omeprazole quadruple therapy group 62 cases,group 4 omeprazole triple therapy treatment group 63 cases,compared four different modes of administration of Helicobacter pylori-positive peptic ulcer efficacy.Results The total effective rate of group 1 and group 2 was 98.33%,the total effective rate of group 3 was 95.16%,and the total effective rate of group 4 was 93.65%.In terms of overall therapeutic effect, rabeprazole was superior to omeprazole,with a statistically significant difference(P<0.05).In rabeprazole-treated group,the effective rate of rabeprazole quadruple therapy was 91.30%,and the effective rate of rabeprazole triple therapy was 73.80%,both of which were statistically significant(P<0.05);In the omeprazole treatment group,the effective rate of omeprazole quadruple therapy was 73.91%,and the effective rate of omeprazole triple therapy was 58.12%.There was a statistically significant difference between them(P＜0.05);Comparing the efficacy of rabeprazole quadruple therapy and omeprazole quadruple therapy,the difference was statistically significant (P<0.05),rabeprazole quadruple therapy was superior to omeprazole quadruple therapy;Comparing the effectiveness of rabeprazole triple therapy and omeprazole triple therapy,the difference was statistically significant(P<0.05).Rabeprazole triple therapy was superior to omeprazole triple therapy.In the eradication of Helicobacter pylori,rabeprazole is superior to omeprazole,and quadruple therapy is superior to triple therapy.Conclusion In the treatment of Helicobacter pylori-positive peptic ulcer, rabeprazole quadruple therapy showed the best therapeutic effect.

参考文献/References:

[1] Chang SS,Hu HY.Helicobacter pylori eradication within 120 days is associated with decreased complicated recurrent peptic ulcers in peptic ulcer bleeding patients[J].Gut Liver,2015,9(3):346-352. [2]Levenstein S,Rosenstock S,Jacobsen RK,et al. Psychological stress increases risk for peptic ulcer,regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs[J].Clin Gastroenterol Hepatol,2015,13(3):498-506. [3]Lee SY.Current progress toward eradicating Helicobacter pylori in East Asian countries:differences in the 2013 revised guidelines between China,Japan,and South Korea[J].World J Gastroenterol,2014,20(6):1493-1502. [4]骆国才,张天辉,张庆.雷贝拉唑三联疗法治疗幽门螺杆菌阳性消化性溃疡84例疗效观察[J].海南医学,2014,25(06):813-815. [5]McLeay SC,Green B,Treem W,et al.Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years[J].Clin Pharmacokinet,2014,53(10):943-957. [6]Graham DY,Shiotani A.New concepts of resistance in the treatment of Helicobacter pylori infections[J].Nat Clin Pract Gastroenterol Hepatol,2008,5(6):321-331. [7]Yang T,Li H,Chen J,et al.Epidemiological study on antibiotic resistance among Helicobacter pylori in Taizhou district,Zhejiang,2010-2013[J].Chin J Epidemiol,2014,35(6):704-707. [8]李向阳,聂萌,苗壮.2种四联疗法治疗幽门螺杆菌感染患者对比观察[J].河南医学高等专科学校学报,2016,28(03):193-194. [9]陈占雄,朱惠琴,谢苗,等.自拟四黄乌贝平胃汤联合四联疗法治疗幽门螺杆菌相关性胃病102例临床疗效观察[J].世界最新医学信息文摘,2016,16(A3):173,185.

相似文献/References:

[1]罗宜辉,刘代华.益生菌联合四联方案根除幽门螺杆菌的临床研究[J].医学信息,2018,31(11):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
　LUO Yi-hui,LIU Dai-hua.Clinical Study on the Eradication of Helicobacter Pylori by Probiotics Combined with Quadruple Regimen[J].Journal of Medical Information,2018,31(11):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
[2]陈艳玲.奥美拉唑、兰索拉唑与泮托拉唑治疗胃炎胃溃疡的效果及安全性[J].医学信息,2022,35(10):134.[doi:10.3969/j.issn.1006-1959.2022.10.032]
　CHEN Yan-ling.Effect and Safety of Omeprazole, Lansoprazole and Pantoprazole in the Treatment of Gastritis and Gastric Ulcer[J].Journal of Medical Information,2022,35(11):134.[doi:10.3969/j.issn.1006-1959.2022.10.032]
[3]张宏程.磷酸铝凝胶联合奥美拉唑治疗消化性溃疡的临床疗效观察[J].医学信息,2019,32(02):150.[doi:10.3969/j.issn.1006-1959.2019.02.044]
　ZHANG Hong-cheng.Clinical Efficacy of Aluminum Phosphate Gel Combined with Omeprazole in the Treatment of Peptic Ulcer[J].Journal of Medical Information,2019,32(11):150.[doi:10.3969/j.issn.1006-1959.2019.02.044]
[4]吕彤观.三联疗法治疗牙周病的临床效果观察[J].医学信息,2018,31(18):129.[doi:10.3969/j.issn.1006-1959.2018.18.041]
　LV Tong-guan.Clinical Observation of Triple Therapy for Periodontosis[J].Journal of Medical Information,2018,31(11):129.[doi:10.3969/j.issn.1006-1959.2018.18.041]
[5]高华初.泮托拉唑治疗消化性溃疡合并上消化道出血的临床价值评价[J].医学信息,2018,31(22):153.[doi:10.3969/j.issn.1006-1959.2018.22.045]
　GAO Hua-chu.Clinical Value of Pantoprazole in the Treatment of Peptic Ulcer Complicated with Upper Gastrointestinal Bleeding[J].Journal of Medical Information,2018,31(11):153.[doi:10.3969/j.issn.1006-1959.2018.22.045]
[6]高华初.奥美拉唑与西咪替丁治疗应激性胃溃疡的疗效观察[J].医学信息,2018,31(23):136.[doi:10.3969/j.issn.1006-1959.2018.23.039]
　GAO Hua-chu.Efficacy of Omeprazole and Cimetidine in the Treatment of Stress Gastric Ulcer[J].Journal of Medical Information,2018,31(11):136.[doi:10.3969/j.issn.1006-1959.2018.23.039]
[7]吴文静.注射用奥美拉唑与注射用艾司奥美拉唑治疗活动期胃溃疡患者的临床效果比较[J].医学信息,2022,35(12):187.[doi:10.3969/j.issn.1006-1959.2022.12.048]
　WU Wen-jing.Effect Comparison of Omeprazole Sodium for Injection and Esomeprazole Sodium Injection in the Treatment of Active Gastric Ulcer Patients[J].Journal of Medical Information,2022,35(11):187.[doi:10.3969/j.issn.1006-1959.2022.12.048]
[8]褚春沐.雷贝拉唑治疗进展性缺血性脑卒中的价值[J].医学信息,2022,35(14):122.[doi:10.3969/j.issn.1006-1959.2022.14.030]
　CHU Chun-mu.Value of Rabeprazole in Treatment of Progressive Ischemic Stroke[J].Journal of Medical Information,2022,35(11):122.[doi:10.3969/j.issn.1006-1959.2022.14.030]
[9]李会颖.奥美拉唑联合多潘立酮治疗哮喘合并胃食管反流病的效果[J].医学信息,2020,33(09):144.[doi:10.3969/j.issn.1006-1959.2020.09.047]
　LI Hui-ying.Effect of Omeprazole Combined with Domperidone on Asthma Combined with Gastroesophageal Reflux Disease[J].Journal of Medical Information,2020,33(11):144.[doi:10.3969/j.issn.1006-1959.2020.09.047]
[10]任 琳.雷尼替丁和奥美拉唑治疗浅表性胃炎的效果比较[J].医学信息,2020,33(12):141.[doi:10.3969/j.issn.1006-1959.2020.12.044]
　REN Lin.Ranitidine and Omeprazole in the Treatment of Superficial Gastritis[J].Journal of Medical Information,2020,33(11):141.[doi:10.3969/j.issn.1006-1959.2020.12.044]

更新日期/Last Update: 2018-06-01